Real-World, Long-Term Quality of Life Following Therapeutic OnabotulinumtoxinA Treatment
| Autor: | Farooq Ismail, Theodore Wein, Grace Trentin, Mandar Jog, Richard D. Beauchamp, Robert M. Miller, Sonja Dhani, Meetu Bhogal |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Canada Pediatrics medicine.medical_specialty Time Factors Adolescent Blepharospasm Acetylcholine Release Inhibitors Cohort Studies Young Adult 03 medical and health sciences 0302 clinical medicine Quality of life Outcome Assessment Health Care Pragmatic Clinical Trials as Topic medicine Humans Hyperhidrosis Hemifacial Spasm 030212 general & internal medicine Cervical dystonia Botulinum Toxins Type A Young adult Prospective cohort study Adverse effect Torticollis Aged Aged 80 and over business.industry Cerebral Palsy General Medicine Middle Aged medicine.disease Health Surveys Clinical trial Treatment Outcome Neurology Muscle Spasticity Cohort Quality of Life Physical therapy Female Neurology (clinical) business 030217 neurology & neurosurgery Cohort study |
| Zdroj: | Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 43:687-696 |
| ISSN: | 2057-0155 0317-1671 |
| DOI: | 10.1017/cjn.2016.262 |
| Popis: | Background:OnabotulinumtoxinA is an efficacious treatment option for patients with various conditions. Although studies have reported on the efficacy of onabotulinumtoxinA, quality of life (QoL) data are limited. This study evaluated QoL in patients treated with onabotulinumtoxinA across various therapeutic indications.Methods:MDs on BOTOX Utility (MOBILITY) was a prospective, multicenter, observational Canadian study in patients initiating (naïve) or receiving ongoing (maintenance) onabotulinumtoxinA treatment. Health utility was the primary outcome measure and was obtained from the Short Form-12 Health Survey using the Short Form-6D at baseline, week 4 posttreatment, and up to five subsequent treatment visits. The safety cohort included patients who received ≥1 onabotulinumtoxinA treatment.Results:The efficacy cohort included 1062 patients; the majority were Caucasian, female, and on maintenance onabotulinumtoxinA treatment. Adult focal spasticity (n=398), blepharospasm (n=81), cerebral palsy (n=22), cervical dystonia (n=234), hemifacial spasm (n=116), and hyperhidrosis (n=211) patients were included. Baseline health utility was generally higher in maintenance versus naïve patients; however, naïve patients showed the greatest improvements over time. Health utility was generally maintained or trended toward improvement across all cohorts, including maintenance patients who had been treated for up to 22 years before study entry. Eighteen of 1222 patients (2%) in the safety cohort reported 28 treatment-related adverse events; eight were serious in four patients.Conclusion:MOBILITY is the largest prospective study to date to provide QoL data over a variety of therapeutic indications following treatment with onabotulinumtoxinA. Although the QoL burden varies by disease, data suggest that long-term treatment may help improve or maintain QoL over time. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|